Granules India on Wednesday informed the exchanges that its subsidiary Granules Pharmaceuticals, Inc has received EIR for its unit located at Chantilly, Virginia.
The US FDA has issued the Establishment Inspection Report for Granules Pharmaceuticals, Inc., a wholly-owned foreign subsidiary. The facility was inspected by the US FDA in December 2017 and there was one observation during the inspection.
The company has responded to the observation within the stipulated time-frame, it further said. Shares of Granules India gained 0.94 per cent at ₹118.40 on the NSE.